Trial Profile

A Phase Ib/II, Open-label, Multicenter Study of Novel Oncology Therapies in Combination With Chemotherapy and Bevacizumab as First-line Therapy in Metastatic Microsatellite-stable Colorectal Cancer (COLUMBIA-1)

Status: Active, no longer recruiting

Phase of Trial: Phase I/II

Latest Information Update: 11 Aug 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Durvalumab (Primary) ; Oleclumab (Primary) ; Bevacizumab; Fluorouracil; Folinic acid; Oxaliplatin
Indications Colorectal cancer
Focus Adverse reactions; Therapeutic Use
Acronyms COLUMBIA-1
Sponsors AstraZeneca AB; MedImmune

28 Jul 2025 Planned End Date changed from 31 Oct 2023 to 24 Nov 2025.
28 Jul 2025 Status changed from discontinued to active, no longer recruiting.
13 Nov 2023 Status changed from completed to discontinued.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com